Asymbescaline

Last updated

Asymbescaline
Asymbescaline.svg
Asymbescaline-3d-sticks.png
Clinical data
Other namesASB; 3,4-Diethoxy-5-methoxyphenethylamine
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action Peak: 2 hours [1]
Duration of action 10–15 hours [1]
Identifiers
  • 2-(3,4-diethoxy-5-methoxyphenyl)ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H21NO3
Molar mass 239.315 g·mol−1
3D model (JSmol)
  • O(c1c(OC)cc(cc1OCC)CCN)CC
  • InChI=1S/C13H21NO3/c1-4-16-12-9-10(6-7-14)8-11(15-3)13(12)17-5-2/h8-9H,4-7,14H2,1-3H3 Yes check.svgY
  • Key:VFOAVFQWZYUFQZ-UHFFFAOYSA-N Yes check.svgY
   (verify)

Asymbescaline (ASB), also known as 3,4-diethoxy-5-methoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. [1] [2] [3] It is the analogue of mescaline in which the methoxy groups at the 3 and 4 positions have been replaced with ethoxy groups. [1] [2] [3]

Contents

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists asymbescaline's dose as 200 to 280 mg orally and its duration as 10 to 15 hours. [1] [2] [3] The time to peak was approximately 2 hours. [1]

The effects of asymbescaline were reported to include a lack of visual and interpretive richness, few if any of the "open interactions" of other psychedelics like 2C-B or LSD, daydreaming, and visions while trying to sleep, and "some negative side". [1] One report described it as a "sort of gentler sister of mescaline", but with a tendency to emphasize the negative such as sadness and struggle. [1] Another report described it as "like being in a corridor outside the lighted halls where a beautiful mescaline experience is taking place, sensing the light from behind a grey door, and not being able to find my way in from the dusky underside passageways". [1] Physical and other side effects included some "body load, physical weirdness, heart rate changes, and insomnia and sleep disruption. [1] Per Shulgin, the consensus from over a half dozen tests was that there was not enough value with the drug to offset its body load. [1]

Interactions

Chemistry

Synthesis

The chemical synthesis of asymbescaline has been described. [1]

Analogues

Analogues of asymbescaline include mescaline, escaline, metaescaline, symbescaline, and trisescaline (trescaline), among others. [1] [2] [3]

History

Asymbescaline was first described in the scientific literature by George S. Grace in 1934. [4] Subsequently, it was described in greater detail by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Asymbescaline". Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. https://www.erowid.org/library/books_online/pihkal/pihkal009.shtml
  2. 1 2 3 4 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on 13 July 2025.
  3. 1 2 3 4 Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID   8742795. Archived from the original on 13 July 2025.
  4. ↑ Grace GS (April 1934). "The action of mescaline and some related compounds". The Journal of Pharmacology and Experimental Therapeutics. 50 (4): 359–372. doi:10.1016/S0022-3565(25)07327-6.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.